Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) expected to beat earnings estimates: Should you buy?
CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports ...
In the latest close session, CRISPR Therapeutics AG (CRSP) was down 8.7% at $55.52. The stock fell short of the S&P 500, which registered a gain of 0.03% for the day. On the other hand, the Dow ...
Artificial intelligence (AI) isn't the only industry with explosive growth potential.
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results